Keyphrases
Acquired Resistance
100%
Dual Inhibition
100%
Immunomodulatory Drugs (IMiDs)
100%
Myeloma Cells
100%
Intrinsic Resistance
100%
Enhancer of Zeste Homolog 2 (EZH2)
100%
Lenalidomide
57%
Genome-wide DNA Methylation
28%
Chromatin Accessibility
28%
Resistant Cell Lines
28%
Smad3
28%
Co-sensitization
14%
Transcriptome Analysis
14%
Epigenetic Reprogramming
14%
5-azacytidine
14%
Continuous Culture
14%
Gene Expression
14%
Stable Resistance
14%
Thalidomide
14%
DNA Methyltransferase 1 (DNMT1)
14%
Mechanism of Action
14%
Downregulated Genes
14%
Multiple Myeloma
14%
Resistant Cells
14%
Biological Targets
14%
Pharmacology, Toxicology and Pharmaceutical Science
Lenalidomide
100%
Myeloma
100%
Transcriptome
25%
Biological Target
25%
Multiple Myeloma
25%
Azacitidine
25%
DNA Methyltransferase
25%
Thalidomide
25%
Immunology and Microbiology
Pomalidomide
100%
Myeloma Cell Line
25%
Biochemistry, Genetics and Molecular Biology